146 related articles for article (PubMed ID: 33179146)
1. Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database.
Hur P; Kim N; Dai D; Piao OW; Zheng JZ; Yi E
Drugs Real World Outcomes; 2021 Mar; 8(1):29-38. PubMed ID: 33179146
[TBL] [Abstract][Full Text] [Related]
2. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
Yi E; Dai D; Piao OW; Zheng JZ; Park Y
J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
[TBL] [Abstract][Full Text] [Related]
3. Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database.
Feldman SR; Tian H; Wang X; Germino R
J Manag Care Spec Pharm; 2019 Apr; 25(4):479-488. PubMed ID: 30556761
[TBL] [Abstract][Full Text] [Related]
4. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
Wolf D; Skup M; Yang H; Fang AP; Kageleiry A; Chao J; Mittal M; Lebwohl M
Clin Ther; 2017 Apr; 39(4):849-862.e6. PubMed ID: 28363696
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ; Pelletier C; Ung B; Tian M
Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
[No Abstract] [Full Text] [Related]
7. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
10. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
11. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.
Meissner B; Trivedi D; You M; Rosenblatt L
J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020.
Merola JF; Dennis N; Chakravarty SD; Villacorta R; Mesana L; Lin I; Wang Y; Shawi M; Pacou M; Baker T; Peterson S
Clin Rheumatol; 2021 Oct; 40(10):4061-4070. PubMed ID: 33934270
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
15. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
16. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
Gu T; Mutebi A; Stolshek BS; Tan H
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
[TBL] [Abstract][Full Text] [Related]
17. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.
Merola JF; Herrera V; Palmer JB
Clin Rheumatol; 2018 Oct; 37(10):2751-2761. PubMed ID: 30051284
[TBL] [Abstract][Full Text] [Related]
18. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
Schwartzman S; Li Y; Zhou H; Palmer JB
Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
[TBL] [Abstract][Full Text] [Related]
20. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.
Greenberg JD; Palmer JB; Li Y; Herrera V; Tsang Y; Liao M
J Rheumatol; 2016 Jan; 43(1):88-96. PubMed ID: 26628601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
